Bone Metabolism

Latest News

Risks, Benefits of Long-Term Drug Therapy for Osteoporosis Reviewed

Long-term osteoporosis drug therapy reduces fracture risk in women but may increase risk for rare adverse events, and research gaps surround use of long-term drug therapies for osteoporotic fracture prevention.

Low Rates of Osteoporosis Screening in Patients With Recent Stroke Despite High Fracture Risk

By

Rachael Beairsto Editor

Rates of osteoporosis screening and treatment are low in patients with recent stroke despite elevated risk for low-trauma fracture.

Ultrasound-Measured Cortical Bone Porosity Linked to Nontraumatic Fracture in Postmenopausal Women

By

Sheila Jacobs

Cortical bidirectional axial transmission measurements may be useful for fracture risk assessment in postmenopausal women.

Abaloparatide Significantly Reduces Fracture Risk in Women With Postmenopausal Osteoporosis

By

Amit Akirov, MD

A meta-analysis showed that abaloparatide treatment reduces the risk for vertebral, nonvertebral, and wrist fractures in postmenopausal women with osteoporosis compared with placebo or other medical treatments.

Outcomes of FRAX-Predicted Risk Treatment Thresholds in Women

By

Amit Akirov, MD

Participants included in the study were women aged 40 and older, with a baseline bone mineral density measure after 1996, and with at least a 5-year follow-up.

Oral Contraceptives Offer Some Protection Against Bone Loss in Anorexia Nervosa

By

Hannah Dellabella

For young women with anorexia nervosa, oral contraceptives may limit bone loss.

Most Osteoporosis Guidelines Do Not Discuss Patient Beliefs, Preferences

Less than 40 percent of osteoporosis clinical practice guidelines include any mention of patients’ beliefs, values, or preferences.

FDA Approves First-in-Class Sclerostin-Inhibitor for Postmenopausal Women at High Risk for Fracture

By

Diana Ernst, RPh

The Food and Drug Administration (FDA) has approved Evenity (romosozumab-aqqg; Amgen) injection for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapies.

Does Parathyroidectomy Reduce CV Risk in Primary Hyperparathyroidism?

By

Amit Akirov, MD

Parathyroidectomy may have a potential beneficial effect on lipid profiles and decrease cardiovascular risk in patients with primary hyperparathyroidism.

Dietary Calcium Intake Unrelated to Postmenopausal Bone Loss in Women With Osteopenia

By

Tyler Rice

There is no association between dietary calcium intake and postmenopausal bone loss.

Treatments for Preventing Fracture in Postmenopausal Women Compared

By

Diana Ernst, RPh

Overall, treatments that were associated with the greatest relative risk reduction in fragility fractures included teriparatide, abaloparatide, denosumab, romosozumab and most bisphosphonate.